Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165659
Status:
COMPLETED
Last Update Posted:
2010-01-29
First Post:
2005-09-12
Brief Title:
A Multi-Center Randomized Double-Blind Parallel Group Study With 3 Groups Receiving Placebo 5 mg of E2020 and 10 mg of E2020
Sponsor:
Eisai Limited
Organization:
Eisai Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the dose-response efficacy of E2020 5 mgday and 10 mgday versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus and SIB as the primary efficacy measures Safety of E2020 will also be evaluated
for overall evalution of clinical symtoms for cognitive function test
for overall evalution of clinical symtoms for cognitive function test
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None